Current pregnancy or lactation 
Liver disease or elevated liver enzymes 
Established diagnosis of diabetes mellitus 
Abnormal serum glucose levels either at fasting or after the 2-hr oral glucose tolerance test meeting criteria for the diagnosis of diabetes mellitus according to the American Diabetes Association. 
Insulin sensitizing treatment within 3 months prior to or during the eight week study period. 
Hormonal treatment involving estrogen or progesterone 3 months prior to or during the study period, with the exception of medroxyprogesterone acetate for withdrawal bleeding. 
Systemic or inhaled corticosteroids. 
Known hypersensitive reaction to cinnamon. 
Patients with seizure disorders, known cardiovascular disease, or cerebrovascular disease. 
Body mass index (BMI)range 20-50 (excluding all women with BMI under 20 or over 50).       
    

NCT01483118_exc_T1
Condition
pregnancy
NCT01483118_exc_T2
Condition
lactation
NCT01483118_exc_T3
Condition
Liver disease
NCT01483118_exc_T4
Condition
elevated liver enzymes
NCT01483118_exc_T5
Condition
diabetes mellitus
NCT01483118_exc_T6
Value
Abnormal
NCT01483118_exc_T7
Measurement
liver enzymes
NCT01483118_exc_T8
Value
elevated
NCT01483118_exc_T9
Measurement
serum glucose levels
NCT01483118_exc_T10
Condition
Abnormal serum glucose levels
NCT01483118_exc_T11
Temporal
at fasting
NCT01483118_exc_T12
Temporal
after the 2-hr oral glucose tolerance test
NCT01483118_exc_T13
Reference_point
the 2-hr oral glucose tolerance test
NCT01483118_exc_T14
Procedure
2-hr oral glucose tolerance test
NCT01483118_exc_T15
Scope
at fasting or after the 2-hr oral glucose tolerance test
NCT01483118_exc_T16
Reference_point
fasting
NCT01483118_exc_T17
Measurement
criteria for the diagnosis of diabetes mellitus according to the American Diabetes Association
NCT01483118_exc_T18
Value
meeting
NCT01483118_exc_T19
Qualifier
meeting criteria for the diagnosis of diabetes mellitus according to the American Diabetes Association
NCT01483118_exc_T20
Condition
diabetes mellitus
NCT01483118_exc_T21
Procedure
Insulin sensitizing treatment
NCT01483118_exc_T22
Temporal
within 3 months prior to eight week study period
NCT01483118_exc_T23
Temporal
during the eight week study period
NCT01483118_exc_T24
Scope
within 3 months prior to or during the eight week study period
NCT01483118_exc_T25
Drug
estrogen
NCT01483118_exc_T26
Drug
progesterone
NCT01483118_exc_T27
Temporal
3 months prior to the study period
NCT01483118_exc_T28
Temporal
during the study period
NCT01483118_exc_T29
Drug
medroxyprogesterone acetate
NCT01483118_exc_T30
Condition
withdrawal bleeding
NCT01483118_exc_T31
Negation
exception
NCT01483118_exc_T32
Drug
inhaled corticosteroids
NCT01483118_exc_T33
Drug
Systemic corticosteroids
NCT01483118_exc_T34
Qualifier
Systemic
NCT01483118_exc_T35
Qualifier
inhaled
NCT01483118_exc_T36
Condition
hypersensitive reaction to cinnamon
NCT01483118_exc_T37
Observation
cinnamon
NCT01483118_exc_T38
Condition
seizure disorders
NCT01483118_exc_T39
Condition
cardiovascular disease
NCT01483118_exc_T40
Condition
cerebrovascular disease
NCT01483118_exc_T41
Measurement
Body mass index (BMI)
NCT01483118_exc_T42
Value
range 20-50